1. Australia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Cann Group Limited

Cann Group Limited

CNGGF
Cann Group LimitedUS flagOther OTC
0.00
USD
- -
- -
1.06MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
0.02
- -
0.02
0.02
0.04
0.03
- -
Basic EPS, GAAP
- -
-0.05
-0.04
-0.07
-0.11
-0.09
-0.07
-0.09
-0.11
- -
Free Cash Flow per Basic Share
- -
-0.01
-0.04
-0.17
-0.23
-0.06
-0.13
-0.01
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.21
0.26
0.64
0.51
0.39
0.32
0.24
0.15
0.03
- -
Tangible Book Value per Share
0.21
0.26
0.64
0.52
0.4
0.33
0.23
0.15
0.03
- -
Basic Weighted Avg Shares
76
56
133
149
152
274
357
393
454
528
Sales/Revenue/Turnover
- -
- -
1
2
1
4
6
14
15
- -
Operating Margin (%)
- -
- -
-1,013.55
-539.17
-2,670.5
-548.45
-453.5
-265.54
-178.89
- -
Depreciation Expense
- -
- -
1
1
2
3
5
12
11
- -
Net Income, GAAP
- -
-3
-5
-11
-17
-25
-26
-34
-51
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-843.9
-465.41
-2,616.94
-584.74
-412.85
-245.26
-333.32
- -
Working Capital
15
11
80
47
7
12
8
-3
-62
- -
LT Debt
- -
- -
- -
- -
9
- -
43
46
- -
- -
Total Equity
16
15
86
77
61
92
85
59
14
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-17.03
-9.5
-13.64
-25.23
-34.05
-30.51
-46.89
-141.23
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
14
2024
- -
- -
- -
- -
15
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.09
2024
- -
- -
- -
- -
-0.11
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Jennifer Lee Pilcher
Full Time Employees
98
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
262-276 Lorimer Street Port Melbourne VIC Australia 3207
IPO Date
Jan 8, 2021
Website
canngrouplimited.com
Similar Companies
Xebra Brands Ltd. (XBRAF)
Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF)
Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ)
The Cannabist Company Holdings Inc. (CBST.NE)
Ecofibre Limited (EOFBY)
Greenrise Global Brands Inc. (XCX.CN)
Business
Cann Group Limited operates as a pioneer in Australia's medicinal cannabis sector, focusing on the comprehensive lifecycle from plant breeding and cultivation through to manufacturing, clinical assessment, and product supply. The company leverages advanced Good Manufacturing Practice (GMP) certified facilities, including a large-scale cultivation and processing site near Mildura, Victoria, and dedicated research and development capabilities in Melbourne, which includes collaborations for genetic improvement. Established in 2014, Cann Group was among the first in Australia to be granted licenses for cannabis research and cultivation for medicinal purposes. Its product portfolio encompasses a variety of medicinal cannabis offerings such as dried flower, oils, and active pharmaceutical ingredients, serving patients within Australia and approved international export markets. The company also features proprietary delivery systems like Satipharm capsules and a diverse product range under its Botanitech brand. Cann Group continues to pursue strategic initiatives, including recent capital raises and debt restructuring, to support its operations and growth within the expanding medicinal cannabis industry.

Company News

APIChat

  • seekingalpha.com

    Cann Group Limited (CNGGF) Shareholder/Analyst Call Transcript

  • accesswire.com

    Cann American Corp. Provides Shareholder Update

  • seekingalpha.com

    Cann Group Limited (CNGGF) Q2 2023 Earnings Call Transcript

  • benzinga.com

    Bearish Wave Tumbles Marijuana Stocks